Evidence map›Paper›PMID 40790833›Full record

ArticleDiabetes/metabolism research and reviews2025

Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects.

Samuel T Jerram, Jennie H M Yang, Evangelia Williams, Clara Domingo-Vila, Yuk-Fun Liu, Mark Peakman, R David Leslie, Timothy Tree

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes/metabolism research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samuel T JerramBlizard Institute, Queen Mary, University of London, London, UK.
Jennie H M YangDepartment of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
Evangelia WilliamsDepartment of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
Clara Domingo-VilaDepartment of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
Yuk-Fun LiuDepartment of Diabetes and Endocrinology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Mark PeakmanDepartment of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
R David LeslieBlizard Institute, Queen Mary, University of London, London, UK.ORCID 0000-0002-1786-1531
Timothy TreeDepartment of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.

Funding

Diabetes UKNovo Nordisk FoundationRosetrees Trust
6 · The paper itself

Abstract

Abatacept is a CTLA4-Ig fusion protein that blocks CD80/CD86-dependent T-cell co-stimulation. When administered, Abatacept limits, to a variable degree, loss of stimulated C-peptide secretion in patients with newly-diagnosed type 1 diabetes (T1D), while reducing both circulating memory CD4

Indexed as

AbataceptDiabetes Mellitus, Type 1Immunosuppressive AgentsAdolescentAdultC-PeptideFemaleFollow-Up StudiesHumansInjections, SubcutaneousMalePrognosisT-Lymphocytes, Helper-InducerT-Lymphocytes, RegulatoryYoung AdultAbataceptC-PeptideImmunosuppressive AgentsAbataceptdiabetesimmunotherapy

Identifiers

PMID40790833
PMCPMC12340168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.